L. V. Moskvina

L. V. Moskvina

Auto-generated profile, based on publicly available information

L. V. Moskvina

Russian Medical Academy of Continuous Professional Education

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2023 in Russian Journal of Archive of Pathology
Verified
Journal Article
Closed access
SVSergey V Vtorushin
Sergey V Vtorushin
NKNadezhda V. Krakhmal
Nadezhda V. Krakhmal
LZL.E. Zavalishina
L.E. Zavalishina
OKO.A. Kuznetsova
O.A. Kuznetsova
LML.V. Moskvina
L.V. Moskvina
GFG.A. Frank
G.A. Frank
A detailed description of the methodological aspects of the evaluation of HER2-status in carcinomas of such localizations as the mammary gland, pancreas, salivary glands, stomach, colon, endometrium, bladder, lungs is presented. Approaches and criteria for assessing HER2 status from methodological and clinical points of view are analyzed. The data are systematized in tables for use in practical diagnostic work.

1 January 2019 in Russian Journal of Archive of Pathology
Verified
Journal Article
Closed access
PDF file
YAYu. Yu. Andreeva
Yu. Yu. Andreeva
LML. V. Moskvina
L. V. Moskvina
GFG. A. Frank
G. A. Frank
LZL. E. Zavalishina
L. E. Zavalishina
OBO. V. Babenko
O. V. Babenko
YPYu. L. Podberezina
Yu. L. Podberezina
To investigate microsatellite instability in smooth muscle tumors of uncertain malignant potential and to compare the results with clinical and morphological data. Histological and immunohistochemical studies were conducted in 26 patients aged 30-63 years (mean age, 37 years) with leiomyomatosis; which revealed intravenous leiomyomatosis in 20 cases, metastasizing leiomyoma in 2, disseminated peritoneal leiomyomatosis in 3, and smooth muscle tumor of uncertain malignant potential in 1 case. Microsatellite instability was studied by fragment analysis on a genetic analyzer using a test system of six markers: D10S1146, D10S218, D10S24, D10S1213, D3S1295, and D9S942. Microsatellite repeat changes characteristic of leiomyosarcomas (heterozygosity loss and/or microsatellite instability in at least one locus studied) were found in 6 patients; all were clinically and morphologically diagnosed as having intravenous leiomyomatosis. In 3 of these 6 cases, leiomyomatosis was accompanied by metastases to the lungs and spread to the peritoneum; heart damage was noted in 2 cases. The data analysis did not allow identification of any significant clinical and morphological criteria for this group. Leiomyomatosis is not a transitional form from benign leiomyoma to leiomyosarcoma, as evidenced by the difference in the status of molecular markers. Analysis of molecular genetic changes in DNA from tumor tissue samples cannot categorically clarify the nature of the disease by identifying the signs of genetic instability; however, there is a need for further accumulation of experience in studying tumors of this group and in identifying the possible association with disease prognosis.

23 April 2023 in Russian Journal of Archive of Pathology
Verified
Journal Article
Closed access
LZL.E. Zavalishina
L.E. Zavalishina
EOE.M. Oliushina
E.M. Oliushina
YAYu.YU. Andreeva
Yu.YU. Andreeva
OKO.A. Kuznetsova
O.A. Kuznetsova
LML.V. Moskvina
L.V. Moskvina
GFG.A. Frank
G.A. Frank
Updated 2023 guidelines from the College of American Pathologists (CAP) on immunohistochemical detection of human epidermal growth factor receptor type 2 (HER2), receptors of estrogen (ER) and progesterone (PgR), and the cell proliferation marker Ki-67 in breast cancer are presented. Attention is drawn to the emergence of two new terms «ER Low Positive» and «HER2 Low» to characterize tumors with low expression of estrogen receptors and HER2.

23 April 2023 in Russian Journal of Archive of Pathology
Verified
Journal Article
Closed access
EOE.M. Oliushina
E.M. Oliushina
LZL.E. Zavalishina
L.E. Zavalishina
YAYu.YU. Andreeva
Yu.YU. Andreeva
OKO.A. Kuznetsova
O.A. Kuznetsova
LML.V. Moskvina
L.V. Moskvina
GFG.A. Frank
G.A. Frank
ЦЕЛЬ ИССЛЕДОВАНИЯ Исследование экспрессии PD-L1 в плоскоклеточном и аденоплоскоклеточном раке шейки матки (РШМ) иммуногистохимическим (ИГХ) методом, оценка связи PD-L1-статуса опухоли с ее клинико-морфологическими характеристиками, TILs, MSI/dMMR и HPV-статусом опухоли. МАТЕРИАЛ И МЕТОДЫ Операционный материал получен у 41 пациентки с РШМ, на котором была исследована экспрессия PD-L1, белков MMR-системы и p16 ИГХ-методом, определен показатель TILs. РЕЗУЛЬТАТЫ В 51,2% исследуемых образцов РШМ был выявлен позитивный PD-L1-статус. В исследуемой выборке уровень экспрессии PD-L1 зависел от выраженности лимфоидной инфильтрации опухоли (p=0,038), показано, что позитивный PD-L1-статус РШМ можно ожидать при значении количественного показателя TILs выше или равном 50%. Возраст пациенток, гистологический вариант опухоли, стадия pT и pN, наличие лимфоваскулярной инвазии и HPV-статус статистически значимо на уровень экспрессии PD-L1 не влияли, однако отмечена связь PD-L1-статуса со степенью злокачественности РШМ (p=0,027). Наличие феномена MSI/dMMR было выявлено в небольшом (4,9%) количестве карцином, PD-L1-статус данных опухолей был определен как позитивный. ЗАКЛЮЧЕНИЕ Позитивный PD-L1-статус определяется в значительном количестве случаев РШМ, независимо от большинства исследованных клинико-морфологических характеристик, отмечается статистически значимая связь экспрессии PD-L1 со степенью дифференцировки опухоли и TILs. Показано, что для РШМ с феноменом MSI/dMMR характерен позитивный PD-L1-статус. Авторы считают необходимым исследовать экспрессию PD-L1 у пациенток с карциномами шейки матки в целях определения возможности назначения им персонализированной терапии препаратами-ингибиторами иммунных контрольных точек.

18 June 2026 in Russian Journal of Archive of Pathology
Verified
Journal Article
Closed access
LML.V. Moskvina
L.V. Moskvina
GRG.A. Raskin
G.A. Raskin
NSN.A. Savelov
N.A. Savelov
YVYa.V. Vishnevskaya
Ya.V. Vishnevskaya
LZL.E. Zavalishina
L.E. Zavalishina
KSKsenya V. Shelekhova
Ksenya V. Shelekhova
This methodology has been developed to standardize the pathology evaluation of melanoma metastasis regression in the sentinel lymph node after neoadjuvant/perioperative immunotherapy in patients with stage III resectable cutaneous melanoma. The methodology is intended for use by pathologists, clinical and surgical oncologists, and healthcare quality assessment experts. It can be implemented as a local protocol for pathological examination, as well as integrated into national clinical guidelines and relevant organizational and methodological documents.

16 October 2026 in Russian Journal of Archive of Pathology
Verified
Journal Article
Closed access
OKO.A. Kuznetsova
O.A. Kuznetsova
EOE.M. Olyushina
E.M. Olyushina
LML.V. Moskvina
L.V. Moskvina
LZL.E. Zavalishina
L.E. Zavalishina
The practical implementation of new immunohistochemical reagents and equipment requires validation in the each pathology department of a medical institution performing intravital diagnostics. This article presents the validation results for reagents and an immunostainer, which required optimizing certain parameters. This enabled reproducible results to those performed using conventional instrument platforms and routine reagents.